Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-1305 mimics are synthetic double-stranded RNA molecules designed to restore the activity of the endogenous tumor-suppressor microRNA-1305 (miR-1305). In pancreatic cancer, miR-1305 is frequently downregulated, which facilitates tumor growth and metastasis. These mimics function by binding to the 3' untranslated regions (UTRs) of target mRNAs, specifically Krueppel-like factor 5 (KLF5) and Receptor tyrosine-protein kinase erbB-2 (ERBB2), leading to their downregulation. This intervention disrupts the KLF5-ERBB2 signaling axis, thereby inhibiting aerobic proliferation, reducing metastatic potential, and inducing apoptosis in cancer cells. Furthermore, miR-1305 and KLF5 participate in a negative regulatory loop where KLF5 suppresses miR-1305 transcription, a cycle that the mimics are intended to break to achieve therapeutic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-1305 mimics.